Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. | ClinicLens
Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non-small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK inhibitor, is safe and effective in such patients is unknown. In this phase 3, do
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.